🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in France / NCT06166810
Recruiting Observational

Capture of Healthy Gut Bacteria Associated to High Fiber Diet

NCT06166810 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2023-10-24
Last updated
2026-06-29

Condition(s) studied

General Population

Study summary

The role of the intestinal microbiota on health is now well recognised, and diet is one of the factors influencing the maintenance of a healthy intestinal microbiota. More specifically, the consumption of fruit, vegetables and cereals is associated with good health and, in particular, with an increase in the relative abundance of bacterial groups described as beneficial. To date, a large number of bacterial species in the intestinal microbiota have yet to be isolated and cultivated, which limits the characterisation of their potential health benefits. In order to isolate and cultivate these intestinal bacteria, it is particularly relevant to recruit individuals with a high-fibre diet.

Eligibility

Sex
ALL
Min age
20 Years
Max age
50 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy adult subjects ; * Age between 20 and 50 (limits included) ; * BMI between 18.5 and 25 kg/m2 (excluding limits) ; * Consumption of more than 5 portions of fruit and vegetables a day; * Intake of at least 25g of dietary fibre per day; * A varied diet with little processed food. Exclusion Criteria: * Antibiotics and/or transit modulators taken in the 3 months prior to sampling; * Known pathologies; * Current treatment; * History of digestive surgery having an impact on the microbiota, deemed incompatible with the study (bariatric surgery); * Consumption of food supplements based on protein preparations, probiotics or prebiotics; * Smoking (even occasionally); * Alcohol consumption \> 2 glasses (i.e. 20 g) per day; * Intense sporting activity; * Pregnant or breast-feeding women; * Persons under legal protection (curatorship, guardianship, etc.); * Volunteers taking part in another intervention study; * Persons refusing to be registered on the French Ministry of Health's Fichier National des Volontaires Sains (National Register of Healthy Volunteers); * Subject not affiliated to the social security system; * Subject in a period of exclusion from a previous study or having received a total amount of compensation exceeding 6000 euros over the 12 consecutive months prior to the start of the trial (after verification in the Fichier des Volontaires pour la Recherche Biomédicale).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
CRNH Auvergne Clermont-Ferrand France Recruiting

More Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06166810 on ClinicalTrials.gov ↗ ← All trials in France